TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian D. Kirkwood, Roslyn J. Francis, Craig Gedye, Natalie K. Rutherford, Alison Yan Zhang, Margaret Mary McJannett, Martin R. Stockler, Scott Williams, Andrew James Martin, Ian D. Davis, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Institutions: The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Sydney, University Health Network, University of Toronto, Princess Margaret Cancer Centre, Royal Brisbane and Women's Hospital, The University of Queensland, Royal Adelaide Hospital, Sir Charles Gairdner Hospital, Calvary Mater Newcastle Hospital, Chris O’Brien Lifehouse, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, The University of Sydney, National Health and Medical Research Council, Eastern Health, Monash University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4286296265